Toni Choueiri: New standard of care for high-risk locally advanced cervical cancer
Toni Choueiri shared a post on X:
”New standard of care for high-risk locally advanced cervical cancer (LACC)?
The phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study shows that the addition of pembrolizumab to concurrent chemoradiotherapy (CCRT) leads to a significant and clinically meaningful improvement in overall survival (OS) with a manageable safety profile!”
Source: Toni Choueiri/X
Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. As a medical oncologist, clinical trialist, and translational researcher, he specializes in treating genitourinary cancers (prostate, bladder, testis, and kidney cancer), with a focus on kidney cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023